ABSTRACT
Introduction
Cytokines are small, serum-soluble proteins that interact with cell surface receptors. These interactions with specific transmembrane receptors activate a cascade of signals that result in a cellular response.
Insulin-like growth factor I (IGF-1; a growth factor similar to insulin) is a cytokine that participates in the cellular granulation process during wound healing. During healing, its expression is increased. However, diabetic patients show overall decreased levels of IGF-1 expression 1 . IGF-1 is a polypeptide consisting of 70 amino acids with a molecular weight of 7.47 kDa with an amino acid sequence that is very similar to insulin. IGF-1 exerts similar effects on growth as insulin. The anabolic effects of IGF-1 include stimulation of DNA synthesis, cell proliferation, protein synthesis, and glucose transport.
Previous studies have shown a relationship between inflammation markers interleukin 6 (IL-6), interleukin 8 (IL-8),
and IGF-1 and microvascular changes in patients with type 1 diabetes. These studies found that IGF-1 levels were decreased in the control group and that IL-6 and IL-8 levels were elevated in patients with type 1 diabetes 2 .
IGF-1 has also been described as an agent that acts anabolically and anti-catabolically in a wide variety of cell types 3, 4 .
In the context of wound healing, the evidence suggests that IGF-1 is mitogenic for keratinocytes and that fibroblasts inhibit the process of apoptosis, thereby reducing the production of inflammatory cytokines and stimulating extracellular matrix production 5 .
IGF-1 expression is modulated during wound healing.
Expression is increased in wound fluid caused by burns and is also significantly increased during the healing process of skin cells, which ordinarily express only small amounts of this protein 3, 6 . This supports the idea that successful healing is associated with IGF-1 levels.
During granulation, tissue fibroblasts develop various structural and biochemical characteristics similar to ultra-smooth muscle cells, including the presence of microfilaments and the expression of α-smooth muscle actin. When the granulation tissue develops into a scar, the myofibroblasts containing α-smooth muscle actin disappear, probably as a result of apoptosis.
The mechanisms leading to myofibroblast development have been investigated elsewhere 7 . Recent studies have reported the mitogenic action of myofibroblast differentiation and proliferation by IGF-1 8, 9 .
During the repair of normal tissues, the controlled activation of myofibroblasts contributes to the restoration of tissue integrity 10 . 
Animals and induction of diabetes
Ninety-six adult male Wistar rats weighing 250 to 300g
were included in the study. Forty-eight animals were non-diabetic and 48 animals were diabetic. Diabetes mellitus (DM) was induced by intravenous administration of alloxan (5,6-dioxouracil monohydrate) with a single dose of 42 mg/kg. Subsequently, the animals were maintained on normal food and water.
Assessment of diabetes
Glucose levels were measured on the 7th and 14th days after induction and were sampled from animals whose blood glucose levels were greater than 250 mg/dl. The results of glucose levels included in the study on the day of induction varied from 69-102 mg/dl on the day 7 to 260-561 mg/dl on day 14 and were between 285-593 mg/dl.
Plasma glucose levels were determined from blood samples collected from the caudal vein using a glucometer AccuChek Advantage II (Roche).
Glycated hemoglobin (HA1C) levels were used as a Diabetic rats, in addition to having high levels of blood glucose and HA1C, also exhibited typical features of the disease, including polyuria, polyphagia, polydipsia, and severe weight loss.
The pathological manifestations of diabetes in the kidneys, retina, and blood vessels are related to metabolic abnormalities caused by the disease over time. Therefore, following the induction of diabetes with alloxan, it was necessary that the diabetic animals were kept for three months prior to the experiment, to give enough time for organic changes to be observed in this group 11 .
Study groups
The animals were divided into six groups of 16. Group 1 included non-diabetic rats receiving no treatment (NDNT), group 2 included in non-diabetic rats that treated with 1% IGF-1 cream (NDIGF1%), group 3 included non-diabetic rats that were treated with 3% IGF-1 cream (NDIGF3%), group 4 included diabetic rats that received no treatment (DNT), group 5 included diabetic rats treated with 1% IGF-1 cream (DIGF1%), and group 6 included rats treated with 3% IGF-1 cream (DIGF3%).
Anesthesia and surgical procedures
Three months after induction of diabetes, all animals received general anesthesia via an intraperitoneal injection of ketamine hydrochloride (75 mg/kg Vetbrands, Jacarei-SP, Brazil) and xylazine (10 mg/kg Vetbrands). After anesthesia, the dorsal region was shaved and antisepsis was performed over the shaved area with chlorhexidine gluconate 2%, and using a autoclavesterilized razor-sharp metal punch, a 0.9-cm fragment of was removed until exposure of the dorsal muscle fascia.
Treatment of surgical wounds
Following this, the animals were reconditioned in specific boxes, divided according to their respective groups, and rats in each group received their assigned treatment, with saline only being administered to the wounds of the animals in groups 1 and 4. This procedure was repeated daily for the duration of the experiment. All rats were examined daily for their mobility, food intake, and water consumption.
Histological analysis
On days 3, 7, 14, and 21 after surgery, the animals were weighed and anesthetized in the same manner as for the initial surgery. The animals were then affixed to the operating table, and the wound was excised with a margin 1 cm of healthy skin around the lesion, incising deeply into the fascia muscle. This time, the tail vein was punctured and blood samples were taken for measurement of HA1C. Following collection of materials, the animals were sacrificed.
Each sample was individually identified, fixed in 10%
formalin solution, and sent to the pathology laboratory where the slides were prepared for histological analysis.
The samples were embedded in paraffin, cut into transverse sections 0.4 mm thick using a microtome, and stained with hematoxylin-eosin (H&E) for comprehensive assessment of 
Immunohistochemical analysis
The immunohistochemical analysis was performed using anti-α-smooth muscle actin (anti α-SMA) (EnvisionTM System-HRP, Dako Cytomation, USA) visualized with diaminobenzidine.
Positive and negative controls were included according to the manufacturer's guidelines. 
Statistical analysis
Statistical analysis was performed using GraphPad Prism Version 6.00 for Windows (La Jolla, California, USA, www.
graphpad.com).
The expression of α-smooth muscle actin in all groups and on all sampled days (3, 7, 14, and 21), and the interaction between them was compared using a two-way ANOVA test.
Nonparametric variables were analyzed using a
Mann-Whitney test. The significance level for rejecting the null hypothesis was 5% (p<0.05).
Results

Macroscopic and histological analysis
No complications were reported in any animals during surgery. There were no deaths prior to euthanasia. Daily clinical evaluations showed adequate recovery rate, maintenance status, presence of physical activity, provision of food, and water intake in all groups. The diabetic animals daily showed signs of diabetes, with obvious weight loss despite increased food intake, and also had polyuria and polydipsia. The hair of the animals in this group was ruffled and yellowish.
The development of skin wounds in all animals showed oozing and delicate crusting up until the seventh day after surgery when the crust thickened and began to detach spontaneously as the healing process progressed.
Skin on the backs of the rats showed a pattern of free subcutaneous and very elastic loose tissue. Depending on the manipulation of the animal and the position in which they were immobilized for the purposes of measuring and photography, the size and appearance of the wounds changed significantly. We therefore considered this to be an unreliable way of analyzing the real effects of IGF-1 on the healing process.
In general, similar wound healing and histological patterns were observed in the animals that were treated with IGF-1 and those that were not. On the third postoperative day, an inflammatory process was observed, presenting congestion, hyperemia, necrosis, inflammatory cells, some collagen deposition, and absence of epithelium. On the seventh day post-surgery, congestion characteristic of the third day was still present, although it was less intense. The inflammatory process was more intense and diffused, with greater presence of inflammatory cells, and intense necrosis. Also on the seventh postoperative day, we observed the presence of new blood vessels (angiogenesis) and a larger number of fibroblasts that induced greater collagen neoformation (fibers were more numerous and more mature-looking) compared to the third day. Additionally, fibrin-leukocyte crusts were present in the wounds of all evaluated animals. On the 14th day after surgery, the wound healing process was advanced, showing a reduction in the inflammatory process characterized by a smaller amount of inflammatory cells, discrete inflammatory infiltration, absence of necrosis, re-epithelization of the tissues and collagen deposition, presenting more differentiated fibers ( Figure 1 ). On the 21st day, the wound healing process was 
Immunohistochemical analysis
Tissue samples subjected to immunohistochemical analysis to compare the expression of α-smooth muscle actin between groups showed a significant difference in the expression of myofibroblasts (Figure 2 ). The ANOVA test confirmed that these differences were statistically significant. The samples showed a peak in the expression of α-smooth muscle actin (α-SMA) on the seventh day, which was higher in the groups treated with IGF. This difference was shown to be statistically significant. Table 1 shows the average value of myofibroblasts in field 10 of the blades subjected to immunohistochemistry (Figure 2 ). In this table, one can see the significant presence of myofibroblasts on the seventh day after surgery, evident both in non-diabetic animals and in animals with diabetes that were treated with either 1% or 3% IGF-1. The specific effects of IGF in wound healing were studied, and it was demonstrated that IGF-1 plays a role in angiogenesis, promotion of collagen synthesis, and stimulation of fibroblasts and keratinocytes. IGF-1 has been found in the epithelium and in the later stages of granulation tissue. Increased expression of these growth factors is therefore related to changes in the wound 3, 6 .
A B
These data support the hypothesis that the difficulties associated with wound healing in diabetic patients are, at Our study found no statistically significant differences in the assessment of the healing process in the analysis of polymorphonuclear cells, vascularization, and inflammation. However, it did demonstrate the effectiveness of the application of IGF-1 in wound healing, which increases the expression of myofibroblasts. The immunohistochemical analysis using antibody α-smooth muscle actin showed that the expression of myofibroblasts was more evident on the seventh postoperative day and was higher in the treated groups.
A significant increase was observed in the expression of myofibroblasts in the animals treated with IGF compared with those that were not treated. This increase occurred in both nondiabetic and diabetic animals, such that the expression in diabetic animals was even more significant than that in non-diabetic animals, suggesting that the receptors for this protein in diabetic animals may also be reduced. However, the increased availability helped to increase the expression of myofibroblasts, which in turn plays an important role in the final process of healing, promoting a more rapid healing process among treated animals.
Several authors have evaluated the use of numerous topical substances to positively influence the healing process.
Obviously, many factors are involved in an effective intervention in the healing process, and accurate clinical diagnosis of the type of the injury and its healing stage is critical because different wounds in different patients require different forms of treatment.
In our study, IGF-1 cream was shown to be effective in the healing process; however, it is important to expand these analyses further. Future studies are needed to overcome the limitations of our experimental design as a whole and also to assess the expression of IGF-1 receptors in diabetic patients, other factors involved in wound healing, and thus evaluate the safety of treatment with IGF-1.
Conclusions
The use of a topical IGF-1 cream on wounds induced a higher expression of myofibroblasts in the wound bed and a consequent improvement in scarring.
In non-diabetic animals treated with IGF-1, the expression of myofibroblasts was higher than that in diabetic animals treated with IGF-1, which may indicate a decrease in IGF receptor expression in diabetic animals. Further studies are necessary to assess the decreased expression of these receptors.
